Biocon Biologics partners with Sandoz Australia

Biocon Biologics partners with Sandoz Australia for biosimilars Trastuzumab and Bevacizumab

Biocon Biologics a  subsidiary of Biocon has now inked  five-year partnership with Sandoz AG which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab with a market value of AUD$ 35 million and biosimilar Bevacizumab with a market value of AUD$ 45 million in Australia.
 
Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, Ogivri (bTrastuzumab) and Abevmy (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin – both biosimilars are available on the PBS and utilised for the treatment of various cancers.
 
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024.
 
Matt Erick, chief commercial officer of advanced markets, Biocon Biologics, said: "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our global partnership and growth strategy. This relationship is also a crucial step for patients in Australia, ensuring continued access to high-quality, affordable biosimilar medicines used in oncology."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!